ASCO 2024 Impact Survey
Explore our new survey on oncologists' views of new cancer treatments, including multi-targeted antibodies and next-gen small molecules.
Our consulting team gathered insights from 60 oncologists who attended the 2024 ASCO Impact Survey. Survey respondents showed strong interest in new treatments like multi-targeted antibodies and next-gen small molecules, indicating key topics such as HER3 and KRAS G12c could change the oncology landscape.
Fill out the form below to download the full report and explore insights from oncologists around the globe.
Related Content
Looking for exclusive insight?
